Filing Flows

Filing Flows › 8-K events › Alamar Biosciences

Alamar Biosciences: results of operations

Form 8-K filed Nov 3, 2026 · items 2.02, 5.02

Results of operationsAlamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

What the filing says

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 5.02: −0.1% next session across 39,174. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Alamar Biosciences at a glance

Latest quarterQ3 2026
Revenue$33.5M
Revenue Y/Y+68%
Operating margin-45.1%
IndustryLaboratory Analytical Instruments

Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%. The chart follows the revenue to costs, profit and cash.

Alamar Biosciences: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent guidance

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.